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Abstract Rhabdomyosarcoma (RMS) is the most common
soft-tissue sarcoma of childhood. This paper is focuses on
imaging for diagnosis, staging, and follow-up of non-
craniofacial RMS.
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Introduction
Rhabdomyosarcoma (RMS) is the most common paediatric
soft-tissue sarcoma and constitutes 3–5% of all malignan-
cies in childhood [1]. In children, the age-standardized
annual incidence rate for RMS is between 4 and 7 per
million [2]. This review focuses on the imaging of all RMS
occurring outside the head and neck region, which
comprise 40% of RMS; around 15% are genitourinary
(GU) nonbladder prostate tumours (GU-NBP, i.e. para-
testicular, vaginal and uterine tumours), 10% are bladder
prostate tumours (BP), 15% occur in the limbs, and 20%
occur in other sites (i.e. thoracic or abdominal tumours).
Clinical symptoms vary widely, based on the location of
the primary tumour, but in general presenting symptoms
often are indolent, with nonspecific or minimal symptoms,
at the start mimicking innocent general paediatric diseases.
Often the duration or progression of symptoms alerts the
physician to the presence of a malignant tumour. Site-
specific symptoms in GU-NBP tumours are a paratesticular
mass in boys that may be painful or not, while girls may
present with a grape-like (botryoid) vaginal extrusion of
mucosanguineous tissue or micturition problems. BP
tumours may present with urinary retention, haematuria,
constipation or an abdominal mass. Limb tumours often
present with a painless swelling and/or with enlarged
regional lymph nodes, while presentation of tumours in
other locations may vary from biliary obstruction in
tumours of the biliary tract, to painless masses, all depend-
ing on their primary site.
Patients with metastatic disease present with more
general symptoms of fatigue, weight loss, and low blood
counts. As soon as a RMS is suspected an extensive work-
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Amsterdam, The Netherlandsup must be performed to get a histological diagnosis and
correct staging of the tumour. Imaging of the primary site
with US, MRI or CT is required in all patients at the start of
the diagnostic work-up [3]. Once the diagnosis has been
confirmed histologically, the most frequently involved
metastatic sites will be investigated; CT of the lungs,
imaging of regional lymph nodes, and a technetium bone
scan are recommended for every patient. Furthermore, bone
marrow aspirates and trephines should be performed in all
patients, while examination of the cerebral spinal fluid is
only required in patients with paraspinal and parameningeal
locations. As soon as the work-up has been completed, the
patient can be stratified to receive treatment according to the
child’s risk group, based on the six significant prognostic
factors for localized RMS that came out of a retrospective
European analysis (European Paediatric Soft-tissue Sarcoma
Study Group, EpSSG); histology, postsurgical status accord-
ing to the Intergroup Rhabdomyosarcoma Study Group
(IRSG), tumour site, node involvement, tumour size, and
patient age (Table 1).
Pathology
RMS is a fast-growing, primitive, high-grade, malignant
mesenchymal tumour. Depending on their degree of
differentiation, the tumour cells manifest features that more
or less can be found in the cells of skeletal muscle. These
features, essential for the diagnosis, are the presence of
myofibrils and cross striations (on light and electron
microscopy) and/or positive immunohistochemical staining
for markers of muscle differentiation such as desmin and
myoD1. For detailed descriptions of the histopathological
aspects of RMS, reference should be made to Weiss and
Goldblum [4] and Fletcher et al. [5].
Based on morphology, RMS is traditionally subdivided
into embryonal, alveolar and pleomorphic. Pleomorphic
RMS, in contrast to embryonal and alveolar RMS, almost
exclusively occurs in adults (median age sixth decade), and
is therefore not discussed further. Embryonal RMS is the
most common type (60–70% of all RMS). The cells show a
close resemblance to various stages in the embryogenesis of
normal skeletal muscle (Fig. 1). Subtypes are botryoid RMS
and spindle-cell RMS (Fig. 2). When arising in the
submucosa, embryonal RMS may present as a fast-growing
exophytic, polypoid mass. This macroscopic variant is called
botryoid RMS (grape-like) and, due to its growth pattern
(primary exophytic and not invasive), has a better prognosis.
Spindle-cell RMS comprising about 4% of all RMS,
seems to behave less aggressively and is most often
encountered in a paratesticular location (about 30% of all
paratesticular RMS) and the head and neck [6, 7].
Histologically spindle cell RMS is characterized by parallel
orientation of spindle cells with an eosinophilic, fibrillary
cytoplasm and an elongated, hyperchromatic nucleus. The
cells are arranged in broad fascicles (fibro-/leiomyosar-
coma-like) or in short, interdigitating fascicles (storiform)
and whirls with, in contrast to the broad fasciculated variant
(leiomyomatous type), an abundant, partly hyalinized
collagenous matrix.
Alveolar RMS is composed of ill-defined, dense aggre-
gates of poorly differentiated round or oval tumour cells
that frequently show loss of cohesion (Fig. 3). This loss of
cohesion and the presence of thin fibrous septa result in an
alveolar pattern. In cases where the tumour cells do not
show loss of cohesion, the term ‘solid alveolar RMS’ is
used. Alveolar RMS represents about 20% of all RMS and
has two specific translocations with specific fusion tran-
scripts that can be detected by RT-PCR. The majority
(about 55%) show a t(2;13)(q35;q14) translocation with the
corresponding fusion transcript PAX3-FKHR [8]. In about
22% a t(1;13)(p36;q14) translocation is found with fusion
transcript PAX7-FKHR. In rare cases, RMS with a more or
less alveolar pattern lacks these translocations.
Table 1 EpSSG prognostic factors [28]
Favourable Unfavourable
Histology Embryonal Alveolar
IRSG status Higher grades more unfavourable
Tumour site Head and neck non-
parameningeal
All other
sites
Orbital
Genitourinary – nonbladder/
prostate
Node
involvement
N0 N1
Tumour size
(cm)
≤5> 5
Age (years) <10 ≥10
Fig. 1 Embryonal RMS: small cells and primitive spindle-shaped
cells resembling the first stages of developing normal skeletal muscle
(H&E, original magnification 10×20)
618 Pediatr Radiol (2008) 38:617–634Both embryonal and alveolar RMS may show rhabdoid
tumour-like features and anaplasia (focal or diffuse) [9, 10].
More recently, under the heading sclerosing RMS, a variant
with hyalin sclerosis has been described (Fig. 4)[ 11]. It is
unclear whether this is a distinct subtype.
In 1995, the IRSG and the International Society of
Paediatric Oncology (SIOP) suggested a prognostically
more significant classification (Table 2)[ 12].
Imaging findings
Radiography
As RMS is a soft-tissue tumour, conventional radiology
plays an insignificant role in its diagnosis. Localized bony
erosion adjacent to the primary site is a recognized
complication; this area may be hot on a 99mTc-MDP bone
scan in the absence of metastatic disease in the skeleton. In
contrast to the initial diagnostic work-up, where for the
assessment of pulmonary metastases CT is mandatory, AP
and lateral chest radiographs are used in the follow-up
period.
Ultrasonography
US is often the first imaging modality used in children with
soft-tissue masses because it is readily available, has high
resolution, and can easily assess extent and vascularity of a
mass. One should not forget that most soft-tissue lesions are
benign, can readily be diagnosed with US, and do not need
further diagnostic work-up or even treatment.
On US, RMS in general shows as a well-defined,
slightly hypoechoic inhomogeneous mass that can show
significantly increased flow (Fig. 5). In the particular case
of paratesticular RMS, US is the imaging modality of
choice, although CT of the abdomen is also necessary to
evaluate for retroperitoneal lymphadenopathy. In all other
RMS locations additional imaging using CT or MRI is
mandatory.
US is also of use in image-guided biopsies. Recently
Sebire and Roebuck [13] systematically reviewed the
pathological diagnosis of paediatric tumours from image-
Fig. 3 Alveolar RMS: cluster of primitive cells with loss of cellular
cohesion and bordered by dense fibrous septa, resulting in an alveolar
pattern (H&E, original magnification 10×20)
Fig. 4 Sclerosing RMS: small cells, primitive spindle-shaped cells
and eosinophilic rhabdomyoblasts in a background of hyaline sclerosis
(H&E, original magnification 10×20)
Fig. 2 Embryonal RMS, spindle-cell type: closely packed spindle cells
arranged in perpendicular crossing fascicles giving a leiomyosarcoma-
like appearance (H&E, original magnification 10×20)
Table 2 RMS: IRSG and SIOP classification, extended with new
variants [12]
Group Prognosis Subtype
I Better prognosis Embryonal RMS, botryoid type
Embryonal RMS, spindle-cell type
II Intermediate
prognosis
Embryonal RMS (remaining)
III Worse prognosis Alveolar RMS
IV Unclear prognosis RMS with rhabdoid features
Embryonal RMS with diffuse
anaplasia
Sclerosing RMS
Pediatr Radiol (2008) 38:617–634 619guided needle-core biopsies. They concluded that image-
guided biopsy material was sufficient to come to a
diagnosis in 94% (95%; CI 92–96%) of patients. Compli-
cations needing treatment, mostly haemorrhage requiring
transfusion, were reported in only 1% of patients. For
image-guided biopsies the material obtained should be
transported fresh to the pathology department. Fixation
should not be performed as this precludes further cytoge-
netic studies.
CT
In order to assess pulmonary metastases from RMS, CT of
the chest is a mandatory examination. However, assessment
of pulmonary involvement can sometimes be difficult.
Although criteria such as number and size of lesions,
morphology (noncalcified, round and well-defined) and
location (inferior lobes, subpleural spaces, branching
vessels) have been applied in adult patients, none has
shown 100% specificity. According to the EpSSG guide-
lines for evaluating chest CT the following criteria with
respect to the diagnosis of pulmonary metastases should be
applied: one pulmonary or one pleural nodule over 10 mm
in diameter, two or more well-defined nodules of 5–10 mm
or five or more lesions >5 mm [3]. This comes with the
assumption that there is no other medical explanation for
these lesions. When there is a high suspicion that a small
lesion is metastatic, and appears to be the only site of
metastatic disease, biopsy may be performed. In the EpSSG
protocol, lung biopsy is not recommended.
With the introduction of multidetector CT (MDCT) the
advantage of MRI of being a multiplanar imaging modality
has been overtaken, and by virtue of its underlying physics,
CT is superior to MRI in detecting osseous changes. The
drawback of CT in children is the use of ionizing radiation.
Since the seminal papers of Paterson et al. [14] and Brenner
et al. [15], we should be aware of the theoretical risk of CT-
induced cancer fatalities and take this into consideration
especially in the work-up of children with cancer, as they
have already proven their tendency to present with a
malignancy early in life [14, 15].
MRI
With its superior ability to depict soft-tissue changes, MRI
is the primary imaging modality in RMS [16]. Although
imaging protocols should be tailored for each individual
patient, they should at least consist of axial T1-W and T2-
W images (for anatomic detail and assessment of neuro-
vascular structures), T1-W images perpendicular to the
axial plane, and imaging after gadolinium administration. It
is important that at least two series should be identical, one
before and one after contrast agent administration, to be
able to discern enhancement. Contrast-enhanced series are
mandatory and ideally be performed with fat saturation.
The imaging characteristics of RMS are relatively
nonspecific. Like most soft-tissue tumours they have
Fig. 5 A 6-year-old boy with a mass in the left scrotum. US image
shows an ill-defined heterogeneous mass surrounding the testis (open
arrow). The mass shows increased flow (solid arrow). Histopathology:
embryonal RMS
Fig. 6 A 13-year-old girl who
noticeda small lumpnear theanus.
a T1-W MR image shows a well-
defined pararectal lesion (arrow).
b After intravenous gadolinium
administration the lesion shows
homogeneous enhancement
(arrow) Histopathology: alveolar
RMS
620 Pediatr Radiol (2008) 38:617–634intermediate signal intensity on T1-W images (Fig. 6). On
T2-W images they tend to be of intermediate-to-high signal
intensity. If the tumour contains a high number of septa it
may have a lobular shape. RMS in general show strong
enhancement on postcontrast imaging (Fig. 6). In very rare
instances the tumour may show a predominantly cystic
appearance (Fig. 7). Dynamic series are useful in order to
assess tumour vascularity, and to differentiate between
postchemotherapy/surgery residual disease and fibrosis.
For the surgeon, in order to plan surgery, it is of
importance to describe the compartment in which the RMS
is located [17]. Vascular involvement is considered to be
absent if there is a normal tissue plane visible between the
tumour and the vessel, or if the tumour has a less then a
180° circumferential relationship. If the tumour surrounds
the vessel for more than 180°, it is considered to be
encased.
Two studies have addressed the use of whole-body MRI
(WB-MRI) in paediatric oncology [18, 19]. In the first
study with various malignant tumours WB-MRI had a
superior positive predictive value for skeletal metastases
compared to bone scintigraphy (94 vs. 76%, respectively),
and also a significantly higher sensitivity (99 vs. 26%,
respectively) [18]. In the second study, WB-MRI had a
higher sensitivity (82%) than skeletal scintigraphy (71%)
for the detection of bone marrow metastases, but a lower
sensitivity than FDG-PET (90%) [19]. The authors of both
studies concluded that WB-MRI can replace bone scintig-
raphy. One advantage of this approach would be the
implementation of a one-stop-shop approach to childhood
RMS. A drawback of MRI in young children is, however,
the need for general anaesthesia.
Bone scintigraphy
In the current EpSSG protocols, bone scintigraphy is
mandatory as part of the work-up in patients with RMS.
The finding of an isolated hot spot on the bone scan should
be evaluated with conventional radiography or MRI.
Cogswell et al. [20] reported a retrospective series of 40,
primarily adult, patients with RMS and found bone
metastases in 18%. Bone scintigraphy in their study had a
sensitivity of 70% and specificity 95% in the detection of
metastatic disease. In contrast to this, in a Dutch study of
109 patients with soft-tissue sarcoma, bone metastases were
found in only 8 patients (7%) [21]. However, of these eight
patients, six reported bone pain and all had other sites of
metastatic disease. The authors conclude that the yield of
routine bone scintigraphy is low and that it should be
reserved for symptomatic or high-risk patients only.
Positron emission tomography-CT
In PET-CT studies fluorine-18 fluorodeoxyglucose (
18F-
FDG), a radiolabelled glucose analogue, is used [22]. As
18F-FDG is a glucose analogue, it shows uptake in
metabolically active cells, which most malignant tumour
cells are. The combination of PETwith CT, without moving
the relative position of the patient, yields a higher
diagnostic accuracy than PET alone (Fig. 8). In general,
the CT scan will be low-dose CT scan only meant to
identify anatomical structures. However, as the CT scanners
in modern PET-CT systems are of high diagnostic quality, it
is also possible to combine a diagnostic CT scan, e.g. for
the depiction of pulmonary metastases, with a PET scan.
Fig. 7 An 8-year-old girl with
haemolysis, fever and a mass
underneath the scapula. a Coro-
nal STIR image shows a lesion
with mixed signal intensity
(open arrow) and multiple en-
larged lymph nodes in the neck
(solid arrow). b Axial T2-W
image shows multiple cystic
lesions with fluid-fluid levels
(open arrow). Histopathology:
stage IV embryonal RMS
Pediatr Radiol (2008) 38:617–634 621The literature on the use of PET-CT in children with
RMS is limited to several case reports or small studies [23,
24]. Although in some cases PET-CT has been shown to be
of benefit in individual patients, larger prospective studies
are needed.
Staging and follow-up
Staging of RMS is of importance for the individual patient
as it gives an indication of prognosis, and thus treatment
stratification. From a broader perspective staging makes
compiling data on larger patient groups for research
purposes possible, enabling evaluation of the outcome of
different treatment regimens.
The main staging system is the postsurgical staging
system developed by the IRSG. This is currently used by
study groups both in the USA and now in Europe also
(Table 3). The IRSG was formed in 1972 and consisted of
surgeons, pathologists, oncologists, and radiation oncolo-
gists. The absence of radiologists is striking, and paediatric
radiologists are still infrequently involved in development
of paediatric oncology study protocols, although in the
EpSSG RMS 2005, paediatric radiologists were involved in
the development of the protocol. For staging regional nodes
it is important to be familiar with the regional node stations.
Lymph node involvement has a negative impact on
prognosis, as has been shown in the SIOP Malignant
Mesenchymal Tumor 89 trial [25]. Overall 5-year survival
was 60% for N1 patients versus 73% in N0 patients (P=
0.03). Distant lymph node involvement upgrades a patient
to stage IV disease (Fig. 7), having an adverse impact on
prognosis: overall 5-year survival becomes 24% [26].
Table 4 lists the regional node stations by primary tumour
site. Oval-shape lymph nodes and a short axis <1 cm are
considered to be normal [3]. If the node shows peripheral
enhancement or is round with a short axis of 1.5–2c mt h e n
the node should be considered probably invaded by tumour.
Besides surgical resection or needle-core biopsies, lymph
node involvement can also be assessed using fine-needle
aspiration (FNA). Klijanienko et al. [27] reported a review of
the use of FNA in 180 tumours; 176 (97.8%) were either
diagnosed accurately or as round-cell sarcoma.
Only in patients with intraspinal or suspected meningeal
extension (on imaging or clinical assessment) does the
EpSSG RMS protocol state that craniospinal MR should
also be performed. In the current EpSSG RMS 2005
protocol, risk stratification is based on six criteria that have
emerged from the analyses of previous European studies:
histology (embryonal vs. alveolar), postsurgical stage
(IRSG), tumour site, node stage, tumour size and patient
age (Table 1)[ 28].
During follow-up, tumour size is an important parameter
in assessing tumour response. In the current EpSSG
protocol complete remission is defined as disappearance
of tumour both clinically and on imaging. Minor response
is defined as >33% reduction in volume after three courses
of chemotherapy; if not reached the patient is eligible for
second-line chemotherapy. In recording tumour response
Fig. 8 A 19-year-old boy with a history of treated metastatic RMS
presented with low back pain. The PET-CT image shows intense
18F-
FDG uptake in the spinal canal (open arrow). Physiological excretion
of the radiopharmaceutical via the kidneys is visible (solid arrows).
Histopathology: embryonal RMS
Table 3 IRSG classification
Stage Characteristics
I Localized disease completely resected (regional
nodes not involved)
A: Tumour confined to muscle or organ of origin
B: Tumour infiltrating outside organ of (muscle of) origin
II Localized or regional disease with total resection of
gross tumour
A: Primary tumour grossly resected, with microscopic residual disease (negative
findings in local nodes)
B: Primary tumour and positive nodes completely resected
C: Primary tumour and positive nodes resected, with evidence of microscopic
residual disease
III Incomplete resection of tumour or biopsy, with gross residual disease
IV Distant metastatic disease present at diagnosis
622 Pediatr Radiol (2008) 38:617–634the EpSSG uses volumetric evaluation; additionally the
presence or absence of a posttherapeutic residue should be
mentioned in the radiology report [28].
In studies in adults the use of Response Evaluation
Criteria In Solid Tumours (RECIST) has been advocated by
the European Organization for Research and Treatment of
Cancer (EORTC), National Cancer Institute of Canada
Clinical Trials Group and the National Cancer Institute
(NCI) of the United States [29]. With respect to implemen-
tation in children, RECIST have been a matter of debate
[30]. Recently RECIST were retrospectively applied to ten
consecutive children with cancer [31]. The authors con-
cluded that tumour size was underestimated and that in
disseminated disease many lesions were either calcified or
too small to measure and, therefore, that RECIST are not
readily applicable in paediatric oncology. Currently the
EpSSG has incorporated RECIST to be used alongside the
volumetric measurements in their latest protocol in order to
prospectively assess the validity of RECIST in a large
patient population with a single tumour type.
Tumour relapse in patients most commonly presents
with locoregional disease (51%) compared to distant
Table 4 Regional node stations by primary tumour site. Disease with involvement of other lymph nodes than those specified in the table should
be classified as stage IV
Anatomical site Node station
Extremity Lower extremity Inguinal, femoral, popliteal nodes (rare)
Upper extremity Axillary, brachial, epitrochlear, and infraclavicular nodes
Genitourinary Bladder, prostate, cervix, uterus, paratesticular Pelvic, retroperitoneal nodes at renal artery level or below
Vagina Retroperitoneal, pelvic nodes at or below common iliac inguinal nodes
Vulva Inguinal nodes
Thoracic Intrathoracic Internal mammary, mediastinal nodes
Retroperitoneum/pelvis Pelvic, retroperitoneal nodes
Trunk Abdominal wall Inguinal, femoral nodes
Chest wall Axillary, internal mammary, and infraclavicular nodes
Other Biliary Liver hilar nodes
Perianal/perineal Inguinal, pelvic nodes (may be bilateral)
Fig. 9 Two years after initial
diagnosis the patient shown in
Fig. 6 presented at the outpatient
clinic complaining of back pain.
a Coronal STIR image of the
pelvis shows discrete increased
signal intensity in the left ischi-
um (open arrow). b Subse-
quently acquired PET-CT image
confirms the presence of recur-
rent disease in the same location
(open arrow). Note excretion of
tracer into the urinary bladder
(solid arrow). c PET-CT image
also shows a second lesion in
the thoracic spine (open arrow).
Additional rib and pleural me-
tastases were also visible (not
visible on this image)
Pediatr Radiol (2008) 38:617–634 623relapse (41%) [32] (Fig. 9). In a retrospective case-based
study the use of PET-CT was advocated; this, however,
needs to be evaluated in larger prospective studies [33].
Tumour locations
Genitourinary
Approximately 25% of all RMS are GU RMS [34, 35]. As
mentioned above, GU RMS can simply be subdivided into
two subgroups based on different prognosis and subsequent
treatment strategy, GU bladder/prostate (GU-BP) being an
unfavourable location (Fig. 10). Tumours at other GU non-
bladder/prostate (GU-NBP) sites, such as a paratesticular
location (testes, epididymis and spermatic cord; Fig. 5),
vagina or uterus (Fig. 11), have a favourable prognosis, and
thus require less-intensive treatment [36–48]. There is a
caveat to MRI of the bladder in RMS: after intravenous
contrast medium administration, layering of contrast medi-
um can occur making it difficult to appreciate bladder wall
enhancement [49]. T2-W sequences can be particularly
useful in this setting to assess bladder wall thickening.
Additional cystoscopy is often warranted [50]. At the end
of treatment, some residual soft-tissue thickening may
persist, and on MRI it is impossible to decide whether this
is residual scarring or tumour; in these cases endoscopic
biopsy is mandatory.
Extremities
RMS of the extremities (Figs. 12 and 13)i sa l m o s ta l w a y s
of alveolar histology, tends to occur in older children and
young adults, is often present with positive regional lymph
nodes, and has a propensity to metastasize to unusual sites;
these negative prognostic factors contribute to the rela-
tively poor prognosis of RMS in this location [51, 52]. In
approximately 12% of patients, nodal involvement is seen
on imaging; however, when nodal dissection is performed
the rate of nodal involvement increases to almost 50%
[53]. This discrepancy between imaging findings and
nodal dissection might be reduced by using high-quality
state-of-the-art US. In current treatment protocols system-
atic biopsy of regional nodes is advocated, even if the
nodes are not palpable or enlarged on imaging; sentinel
node procedures are recommended whenever feasible,
although the value of upgrading a patient to a higher risk
group based merely on a positive sentinel node has not
been studied yet. As in all tumours of the extremities,
preoperative imaging plays a vital role in the depiction of
Fig. 11 A 2-year-old girl pre-
sented with a mass in the
vagina. a Axial T1-W contrast-
enhanced image shows the mass
with heterogeneous enhance-
ment. The tumour has both solid
(asterisk) and fluid (open arrow)
compartments. b Sagittal T2-W
MR image shows the mass with
mixed signal intensity. The
bladder is displaced anteriorly
and the uterus cannot be visual-
ized. Histopathology: embryonal
RMS
Fig. 10 A 3-year-old boy with RMS of the prostate. The sagittal T1-
W contrast-enhanced MR image shows the lesion invading the bladder
wall. A transurethral catheter has been inserted (open arrow).
Histopathology: botryoid RMS
624 Pediatr Radiol (2008) 38:617–634the relationship between neurovascular bundles and the
tumour.
Other
Chest wall
Chest wall RMS (Fig. 14) is a relatively rare finding with a
reported incidence of 3.7% in the IRSG II and IRSG III
studies [54]. Most of the reports of chest wall involvement
are either case reports or small series [55–57]. In a
retrospective analysis of 15 patients, Saenz et al. [57]
found a 5-year survival of 67%.
Pulmonary
There is an ongoing debate and controversy whether
congenital cystic anomalies predispose children to intrale-
sional development of RMS [58–62]. It has been reported
that pleuropulmonary blastoma (PPB) has been mistaken for
or classified as RMS arising in congenital cystic adenoma-
toid malformation (CCAM) on a number of occasions [63].
Despite the fact that the exact incidence in CCAM is
unknown, it has prompted paediatric surgeons to resect even
small pulmonary cystic lesions (Fig. 15)[ 64, 65].
Biliary tree
RMS is the most common tumour of the biliary tree in
childhood,althoughitonlyaccountsforapproximately0.04%
of all childhood tumours [66]. The initial diagnosis will, in
most patients, be made on US, which may show a solid or
cystic mass situated in the liver hilum, and intrahepatic bile
duct dilatation (Fig. 16). MRI is mandatory for presurgical
evaluation, where magnetic resonance cholangiopancreato-
graphy (MRCP) can depict the biliary tree (Fig. 16). In many
patients, however, endoscopic retrograde cholangiopancrea-
tography (ERCP) will have to be performed in order to
depict intraductal irregularities (Fig. 16). Biliary tree RMS is
a tumour that does not necessarily need to be fully resected
in order to achieve long-term survival, as long as adequate
radiotherapy is added [67]. Intraperitoneal metastases, which
can also be found on follow-up, should also be born in mind.
Other locations
In extremely rare instances RMS can be found in other
organs such as the heart, the diaphragm (Fig. 17), the
omentum, the urachus and the digestive tract [68–76].
Congenital
RMS has been reported to occur as a congenital tumour
(Fig. 18)[ 77–81]. In congenital alveolar RMS the progno-
Fig. 13 A 2-month-old boy with a mass in the third ray of the left
foot. T1-W MR image shows a discrete lesion (open arrow)o f
intermediate signal intensity. Histopathology: embryonal RMS
Fig. 12 A 4-year-old girl pre-
senting with a mass in the left
lower leg. a Axial T1-W con-
trast-enhanced MR image shows
an ill-defined mass circumfer-
ential to the fibula. Note the
cortical thinning (open arrow)
of the fibula. b Sagittal PD-
weighted image shows diffuse
bone marrow metastases. Histo-
pathology: embryonal RMS
Pediatr Radiol (2008) 38:617–634 625sis is reported to be extremely poor, despite otherwise
adequate treatment [79]. Orbach et al. [82] reported the
SIOP data on soft-tissue sarcoma in the first year of life. In
their study population of 16 newborns, with a follow-up of
1.8–10.0 years, 3 out of 5 newborns with RMS survived. It
has been noted that in congenital RMS the disease may be
metastatic at the time of birth, with metastases described in
a number of organs and in the placenta [81].
Adult patients
Every once in a while paediatric radiologists and paediatric
oncologists receive a request for help in the management of
an adult patient (Fig. 19). RMS, although seen as a soft-
tissue tumour of childhood, can also occur later in life [83–
86]. Compared to childhood RMS, adult RMS has a poor
outcome. In a large retrospective study of 171 patients 5-
year overall survival was only 40% [85]. However, the
patients in this series treated according to the guidelines for
treatment of childhood RMS showed survival figures
comparable to those seen in children. This suggests that
treatment of adult RMS should be based on paediatric
protocols tailored to adults, to increase survival in this age
group. In the Academic Medical Centre Amsterdam we
have a working group on childhood tumours in (often
young) adults that specifically deals with this challenging
population. This working group consists of medical
oncologists, paediatric oncologists, radiation oncologists,
(orthopaedic) surgeons and a paediatric radiologist. Imag-
ing features will in general not be of help, as the pretest
likelihood of RMS in an adolescent or adult is extremely
low.
Differential diagnosis
Given the wide variety of locations in which RMS can be
found it is difficult to give a concise list of differential
diagnoses. The site of the primary lesion determines the
differential diagnosis. Keeping location out of the equation
there are, however, certain tumours, such as haemangiomas/
vascular malformations (Fig. 20), adult-type soft-tissue
sarcomas, peripheral neuroectodermal tumours (PNET),
infantile fibrosarcoma, aggressive fibromatosis, desmoplas-
tic small round-cell tumours and rhabdoid tumours, and
other more even rarer soft-tissue tumours such as non-
osseous Ewing sarcoma (Fig. 21), that should be kept in
mind when performing US or reading CT or MRI studies of
soft-tissue tumours in childhood.
Treatment and prognosis
Treatment of RMS requires a multidisciplinary approach,
where chemotherapy, surgery and radiotherapy (RT) each
has its own specific role.
Fig. 15 A 3-year-old boy with dyspnoea. Chest CT image shows
displacement of the trachea (open arrow) and oesophagus (solid
arrow) to the right due to a large mass (asterisk) with accompanying
pleural effusion. Histopathology: embryonal RMS
Fig. 14 A 4-year-old boy presenting with a mass on the right chest
wall. a US image shows a heterogeneous mass in the pectoralis major
muscle (the pectoralis minor is not involved; asterisk). b T1-W MR
image of the chest shows a mass of intermediate signal intensity. c
After intravenous contrast medium administration the lesion shows
homogeneous enhancement. Histopathology: alveolar RMS
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Before the introduction of chemotherapy only 25% of
patients with RMS survived, despite adequate local therapy.
This indirectly indicates that the vast majority of patients
had at least minimal disseminated disease at diagnosis,
whereas, with state-of-the-art imaging techniques and bone
marrow investigations, only 15% of patients with RMS
present with overt metastatic disease. Besides treating
minimal disseminated disease, chemotherapy enables local
therapy to be more conservative. In most patients, surgery
at diagnosis consists of biopsy only. Chemotherapy is given
to all patients; it reduces tumour size and extension and
often allows a delay in surgery. The tumour is more likely
to be completely resected and mutilating surgery avoided.
Most international protocols use vincristine and dactino-
mycin as standard drugs. The choice of alkylating agent
differs between Europe (ifosfamide) and North America
(cyclophosphamide). These drugs have proved to be equally
effective, but differences in toxicity exist: ifosfamide is
more nephrotoxic, whereas cyclophosphamide more gona-
dotoxic [87]. The addition of other antineoplastic agents to
vincristine, dactinomycin and alkylators in the treatment of
RMS has been investigated, but no significant improvement
in outcome has been found [88].
Surgery
In children surgery often starts during the diagnostic phase
with biopsy for histological studies, although here interven-
tional radiology plays an increasing role. Excisional biopsy
is not advocated except for paratesticular tumours. Most
patients end up with postsurgical stage IRS group III.
Surgery is generally delayed until after tumour reduction by
chemotherapy. The surgical treatment of RMS is site-
specific, but the current paradigm is complete wide excision
of the primary tumour with a margin of uninvolved tissue
Fig. 16 An 8-year-old boy pre-
sented with abdominal pain and
jaundice. a US image shows a
central process in the liver hilum
(open arrow) and dilatation of
the intrahepatic bile ducts (solid
arrow). b T2-W MR image
shows a circumscribed lesion
with increased signal intensity
(open arrow). c MRCP image
shows intrahepatic bile duct di-
latation. Note that the right and
left duct systems do not com-
municate (open arrow). d ERCP
image (ERCP performed in or-
der to insert a stent in the
common bile duct). Histopa-
thology: embryonal RMS
Fig. 17 A 4-year-old boy was shown to have a right-sided pleural
effusion on a chest radiograph. Balanced FFE sagittal MR image
shows a mass (open arrow) arising from the diaphragm (courtesy of S.
G.F. Robben, Academic Hospital Maastricht, The Netherlands)
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should be avoided.
Radiotherapy
The philosophies underlying the treatment strategies in
North America and Western Europe have differed in the
past. North American protocols involved aggressive surgery
and routine RT, except for those tumours that were
microscopically radically resected at diagnosis, followed
by prolonged chemotherapy regimens for up to 2 years. The
SIOP-MMT (International Society for Paediatric Oncolo-
gy–Malignant Mesenchymal Tumour) group advocated the
use of chemotherapy and surgery in order to achieve
complete remission in as many patients as possible in order
to avoid RT in these often very young patients. RToften has
devastating effects in growing children, potentially leading
to significant cosmetic and functional problems. Radiation
tolerance of growing bone is ≤20 Gy, but the radiation dose
from the treatment of RMS ranges from 36 to 50.4 Gy. For
certain sites this policy worked out well (e.g. orbital RMS),
and in many patients RT could be avoided [89]. At most
other sites, relapse rates were high, and salvage rates after
relapse were low. The treatment protocols in Germany (Co-
operative Weichteilsarcom Studie, CWS) and Italy (Italian
Cooperative Soft Tissue sarcoma Group, ICG) were
between that in North America and that of the SIOP-
MMT group. In 2005, the former SIOP-MMT, CWS and
ICG joined to form the EpSSG. As a result of extensive
cooperation between the European and the North American
groups, the similarities in treatment strategies now outnum-
ber the differences [90]. Although RT is still deemed
essential in many patients to achieve cure, the possibility of
radiation-induced second malignant neoplasms must be
kept in mind [91, 92].
European approach
Today more than 70% of nonmetastatic RMS are cured, but
survivors may suffer from sequelae [93–98]. Therefore, the
SIOP-MMT group has tried in their RMS75, MMT84,
MMT89 and MMT95 studies to avoid mutilating surgery
and RT [93, 99, 100]. Only children ≥3 years of age with
parameningeal RMS at high risk of meningeal extension
and children not achieving complete remission after
chemotherapy and surgery were irradiated after intensive
chemotherapy. Of all survivors, 49% were treated without
significant local therapy [93]. Locoregional relapse oc-
curred in 34%. This has lead to an event-free survival (EFS)
of 57% and an overall survival (OS) of 71% [93]. Alveolar
histology was associated with a significantly higher risk of
relapse and a much higher risk of metastases.
North American approach
In the studies performed by the IRSG the need for RT is
based on surgical radicality, localization, and size of the
Fig. 19 A 45-year-old man with a mass in the thigh. T1-W contrast-
enhanced MR image shows a heterogeneous circumscribed mass in
the vastus lateralis muscle of the right leg. Histopathology: alveolar
RMS
Fig. 18 A 4-day-old girl born
with a lump on the left foot.
Antenatal ultrasonography at
20 weeks showed no abnormal-
ities. a T1-W MR image shows
a large inhomogeneous mass
arising from the left foot. b
Abdominal US image shows
popliteal and inguinal nodal in-
vasion, and hepatic and pancre-
atic metastases (open arrow).
Due to the poor prognosis, no
therapy was given, and the child
died several weeks later. Histo-
pathology: poorly differentiated
soft-tissue sarcoma without dis-
tinct translocations
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group I) with a favourable location (stage I; Table 5), and
small tumours (≤5 cm) at unfavourable locations (stage II)
did not receive RT in the IRS-IV study [87]. Grossly
resected tumours with microscopic residual disease (IRS
group II), and incompletely resected tumours or tumours
with gross residual disease after biopsy (IRS group III)
were irradiated [87, 88, 101, 102]. With this approach in the
IRS-IV study an EFS of 78% and an OS of 84% were
obtained. Between the IRSG and SIOP-MMT group a
significant difference in OS in alveolar RMS was seen
(71% vs. 38%) [90]. The salvage rate after relapse of an
alveolar RMS was low, and therefore in the current
European trial, RT is mandatory for all patients with
alveolar histology.
As described above, European and American approaches,
although historically different, have converged based on the
results of successive international trials and extensive
cooperation between the European and North American
groups [90]. As approaches now are very similar, in this
review the current EpSSG approach for the different
clinical groups is discussed.
Current EpSSG approach
IRS group I In the IRS-I study, a randomized trial in
clinical IRS group I patients, no difference was seen in
survival between patients treated with chemotherapy and
those treated with chemotherapy and RT [101]. A subse-
quent retrospective study based on the subsequent IRS-I to
IRS-III trials confirmed that for embryonal RMS although
there was a small difference in failure-free survival (FFS)
with and without RT, OS was not significantly different
[103]. On the other hand, for alveolar RMS and undiffer-
entiated RMS, 10-year FFS was 73% vs. 44%, and OS 82%
vs. 52% for patients treated with and without RT,
respectively [103]. Therefore the current EpSSG study
recommends RT in non-embryonal RMS only.
IRS group II Evaluation of the role of RT in IRS group II
patients in subsequent Cooperative Soft Tissue Sarcoma
studies (CWS 81, 86, 91 and 96) showed that for
embryonal RMS, EFS was significantly different for
patients treated with and without RT [104]. However, OS
at 5 years was not significantly different (84% vs. 77%).
For patients with tumours of unfavourable histology
(independent of site and size), EFS and OS were signifi-
cantly better when RT was part of the treatment [104].
Therefore, in IRS group II patients, RT is recommended. It
is compulsory in patients with high-risk features, but may
be omitted in patients with favourable histology in whom
RT may be considered too toxic when considering patient
age and site of the tumour.
IRS group III In patients with IRS group III tumours, RT is
the only available therapy in patients who cannot receive a
secondary complete resection. Patients who do receive a
delayed complete resection benefit from additional RT. In
Fig. 20 A 1-year-old girl with a mass on the left buttock. a Duplex
US image shows a highly vascularized, well-delineated heterogeneous
mass that was initially thought be a haemangioma. b Coronal STIR
image shows a circumscribed solid lesion that invades the pelvis via
the greater sciatic foramen (open arrow). c After initial resection, with
incomplete margins, tumour recurrence was seen. MR image 2.6 years
after initial diagnosis shows progression of disease extending to the
abdominal wall (open arrow). Histopathology: alveolar RMS
Fig. 21 A 22-month-old boy with a mass in the right groin. MRI
shows a heterogeneous lesion adjacent to the gracilis muscle (open
arrow). Histopathology: extraosseous Ewing sarcoma
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those treated with and without additional RT, respectively
[28]. OS, however, was not significantly different between
the two groups: 84% and 79%, respectively. RT is,
therefore, usually indicated except in patients with a
favourable site and histology.
Prognosis
As malignant tumours in childhood are rare diseases, most
children with cancer have been included in international
treatment protocols. This way survival for localized disease
(85% of patients) has improved from 25% in the early
1970s to 75% in the most recent international trials [101,
105–107]. Although results for localized RMS have
improved dramatically in the past decades, patients with
disseminated disease still have a dismal prognosis, with a 5-
year OS of 24% [26].
A way to reduce long-term sequelae of RT may be by
using brachytherapy, especially in girls with genital tract
RMS and patients with bladder-prostate, extremity, and
head and neck RMS [100, 108–111]. Other options are the
use of modulated RT (IMRT) and proton therapy [112,
113].
The postoperative patient
Image interpretation and management of the patient after
surgery and often RT are challenges (Fig. 22). Most
important is proper knowledge of the surgical procedure
Table 5 Pediatric Oncology Group and Children’s Cancer Group for the Study of Rhabdomyosarcoma classification [28]
Stage Site Primary tumour
a Size
b Regional nodes
c Distant metastasis
d
I Orbit T1 or T2 a or b N0, N1 or NX M0
Head and neck (excluding parameningeal)
Genitourinary, nonbladder nonprostate
II Bladder and prostate T1 or T2 a N0 or NX M0
Extremity
Cranial parameningeal
Other (including trunk, retroperitoneum, etc)
III Bladder and prostate T1 or T2 a N1 M0
Extremity
Cranial parameningeal T1 or T2 b N0, N1 or NX M0
Other (including trunk, retroperitoneum, etc)
IV All sites T1 or T2 a or b N0 or N1 M1
aT1 tumour limited to original muscle or organ, T2 tumour has extension or fixation to the surrounding tissue.
ba tumour equal to or less then 5 cm in greatest dimension, b tumour larger than 5 cm in greatest dimension.
cN0 no clinical involvement of regional nodes, N1 clinical involvement of regional nodes, NX status of regional nodes unknown.
dM0 no distant metastasis, M1 distant metastasis.
Fig. 23 Flow chart for posttreatment lesions found on MRI. SI signal
intensity, CE contrast-enhanced [114]
Fig. 22 A 6-year-old boy with a history of treated bladder RMS. At
surgical resection the urethra was damaged leading to a persistent
urinoma in, after RT, nonvital tissue. MRI image after treatment shows
a mass (asterisk) between the urethra (open arrow) and the rectum
(solid arrow). This mass is a vascularized gracilis muscle flap used to
repair the defect. Without proper knowledge of the surgical history of
the patient, this might have been interpreted as tumour recurrence.
Histopathology: embryonal RMS
630 Pediatr Radiol (2008) 38:617–634and/or the radiation field. The following postoperative
changes can be encountered in children treated for RMS:
& Haematoma
& Oedema
& Soft-tissue infection/abscess
& Calcification
& Foreign bodies
& Muscle flaps/fat pads
& Distorted anatomy
& Radiation effect
Figure 23 shows a possible decision tree to manage
postoperative findings on follow-up imaging.
Conclusion
In this review we have discussed the findings of RMS
outside the craniofacial region. The treatment of RMS
requires a multidisciplinary approach, in which paediatric
oncologists, radiologists, paediatric surgeons, pathologists
and radiation oncologists all play a vital role. Although they
are the most common soft-tissue tumour of childhood, these
still rare tumours should be evaluated and treated in
specialized centres.
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